

## References

- Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012). Oral anticoagulant therapy antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *CHEST Journal*, *141*(2), e44S–e44S. <https://doi.org/10.1378/chest.11-2292>
- American College of Chest Physicians. (n.d.). *Guidelines & Resources*. <https://www.chestnet.org/Guidelines-and-Resources>
- American Society of Hematology. (n.d.). *ASH Clinical Practice Guidelines*. <https://www.hematology.org/Clinicians/Guidelines-Quality/Guidelines.aspx>
- Anticoagulation Forum. (2019). *Core Elements of Anticoagulation Stewardship Programs*. [https://acforum-excellence.org/Resource-Center/resource\\_files/-2019-09-18-110254.pdf](https://acforum-excellence.org/Resource-Center/resource_files/-2019-09-18-110254.pdf)
- Armstrong, M.J. (2017, Jun.). Shared decision-making in stroke: An evolving approach to improved patient care. *Stroke and Vascular Neurology*, *2*(2): 84–87. [10.1136/svn-2017-000081](https://doi.org/10.1136/svn-2017-000081)
- Apostolakis, S., Lane, D.A., Guo, Y., Buller, H., & Lip, G.Y. (2012, Aug. 28). Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. *Journal of the American College of Cardiology*, *60*(9):861-7.
- Boehringer Ingelheim Pharmaceuticals, Inc. *Praxbind (idarucizumab)*. (2015). [Package Insert]. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/761025lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf)
- Burnett, A.E., Mahan, C.E., Vazquez, S.R., Oertel, L.B., Garcia, D.A., & Ansell, J. (2016, Jan. 16). Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. *Journal of Thrombosis and Thrombolysis*, *41*: 206. <https://doi.org/10.1007/s11239-015-1310-7>
- Camm, A.J., Lip, G.Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S.H., Hindricks, G., Kirchhof, P., & ESC Committee for Practice Guidelines (CPG). (2012, Nov.). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *European Heart Journal*, *33*(21):2719-2747. [10.1093/eurheartj/ehs253](https://doi.org/10.1093/eurheartj/ehs253)
- Coulter, A. & Ellins, J. (2007, Jul. 7). Effectiveness of strategies for informing, educating, and involving patients. *BMJ*, *335*(7609):24-7. <https://doi.org/10.1136/bmj.39246.581169.80>
- Dickerson, R.N., Garmon, W.M., Kuhl, D.A., Minard, G., & Brown, R.O. (2008, Mar.). Vitamin K-independent warfarin resistance after concurrent administration of warfarin and continuous enteral nutrition. *Pharmacotherapy*, *28*:308-13. [10.1592/phco.28.3.308](https://doi.org/10.1592/phco.28.3.308)

- Elwyn, G., Laitner, S., Coulter, A., Walker, E., Watson, P., & Thomson, R. (2010, Oct. 14). Implementing shared decision making in the NHS. *BMJ*. 341:c5146. 10.1136/bmj.c5146
- European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. *Thrombosis and Haemostasis*. 106(12):997-1011. 10.1160/TH11-10-0690
- European Society of Cardiology. (n.d.). *Novel Oral Anticoagulants for Atrial Fibrillation: EHRA Practical Guide to NOAC Use in AF*. <https://www.escardio.org/Guidelines/Recommended-Reading/Heart-Rhythm/Novel-Oral-Anticoagulants-for-Atrial-Fibrillation>
- Ferguson, C., Inglis, S.C., Newton, P.J., Middleton, S., MacDonald, P.S., & Davidson, P.M. (2015, Apr.). The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review. *European Journal of Cardiovascular Nursing*. 14(2):98-107. 10.1177/1474515114547647
- Friberg, L., Rosenqvist, M., & Lip, G.Y. (2012, Jun.). Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *European Heart Journal*. 33(12):1500-10. 10.1093/eurheartj/ehr488
- Golden State Medical Supply. (2020, Apr. 13). *Warfarin sodium*. MedLibrary. <https://medlibrary.org/lib/rx/meds/warfarin-sodium-47/>
- Greenes, R. (2011). *Clinical decision support: The road ahead*. Academic Press
- Harrington, J., Noble, L.M., & Newman, S.P., (2004, Jan.). Improving patients' communication with doctors: A systematic review of intervention studies. *Patient Education and Counseling*. 52(1):7-16. 10.1016/s0738-3991(03)00017-x
- Hirsh, J., Fuster, V., Ansell, J., Halperin, J.L., American Heart Association, & American College of Cardiology Foundation. (2003, Apr. 1). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. *Circulation*. 107(2):1692-711. 10.1161/01.CIR.0000063575.17904.4E
- ISMP. (2017, Jul. 12). Annual report issue. *ISMP QuarterWatch*. [https://www.ismp.org/sites/default/files/attachments/2018-01/2016Q4\\_1.pdf](https://www.ismp.org/sites/default/files/attachments/2018-01/2016Q4_1.pdf).
- International Society on Thrombosis and Haemostasis. (n.d.). *Published Guidance*. ISTH. [https://www.isth.org/page/Published\\_Guidance](https://www.isth.org/page/Published_Guidance)
- January, C.T., Wann, L.S., Calkins, H., Chen, L.Y., Cigarroa, J.E., Cleveland, J.C., Ellinor, P.T., Ezekowitz, M.D., Field, M.E., Furie, K.L., Heidenreich, P.A., Murray, K.T., Shea, J.B., Tracy, C.M., & Yancy, C.W. (2019, Jan. 28). 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. *Circulation*.
- Kaiser, K., Cheng, W.Y., Jensen, S., Clayman, M.L., Thappa, A., Schwiep, F., Goldberger, J.J., Col, N., & Schein, J. (2015, Dec.). Development of a shared decision-making tool to assist patients and clinicians with decisions on oral anticoagulant treatment for atrial fibrillation. *Current Medical Research and Opinion*. 10.1185/03007995.2015.1096767

- Lavoie, K., Turgeon, M.H., Brais, C., Larochelle, J., Blais, L., Farand, P., Letemplier, G., Perreault, S., & Beauchesne, M.F., (2016, Dec. 31). Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. *Journal of Atrial Fibrillation*. 9(4):1478. 10.4022/jafib.1478
- Lip, G.Y., Andreotti, F., Fauchier, L., Huber, K., Hylek, E., Knight, E., Lane, D., Levi, M., Marin, F., Palareti, G., Kirchhof, P., & European Heart Rhythm Association. (2011, Dec.). Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the
- Lip, G.Y.H., Banerjee, A., Boriani, G., Chiang, C.E., Fargo, R., Freedman, B., Lane, D.A., Ruff, C.T., Turakhia, M., Werring, D., Patel, S., & Moores, L. (2018, Nov.). Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. *CHEST*. 10.1016/j.chest.201807.040.
- Lourenço, R. (2001, Apr.). Enteral feeding: drug/nutrient interaction. *Clinical Nutrition*. 20:187-93. 10.1054/clnu.2000.0155
- Makaryus, J.N., Halperin, J.L., & Lau, J.F. (2013, Jul.). Oral anticoagulants in the management of venous thromboembolism. *Nature Reviews Cardiology*. 10(7):397-409. 10.1038/nrcardio.2013.73
- Man-Son-Hing, M., Nichol, G., Lau, A., & Laupacis, A. (1999, Apr. 12). Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. *Archives of Internal Medicine*. 159(7):677-685. 10.1001/archinte.159.7.677
- Mayo Clinic Staff. (n.d.). *Prothrombin time test*. Mayo Clinic. <https://www.mayoclinic.org/tests-procedures/prothrombin-time/about/pac-20384661>
- Neale, T. (2018, May 4). *Andexanet alfa, first reversal agent for factor Xa inhibitors, finally gains FDA approval*. TCTMD. <https://www.tctmd.com/news/andexanet-alfa-first-reversal-agent-factor-xa-inhibitors-finally-gains-fda-approval>
- Ogilvie, I.M., Newton, N., Welner, S.A., Cowell, W., & Lip, G.Y., (2010, Jul.) Underuse of oral anticoagulants in atrial fibrillation: A systematic review. *American Journal of Medicine*. 123(7):638-645.e4. 10.1016/j.amjmed.2009.11.025
- Palacio, A.M., Kirolos, I., & Tamariz, L. (2015, Jan. 22). Patient values and preferences when choosing anticoagulants. *Patient Preference and Adherence*. 9:133–8. 10.2147/PPA.S6429
- Penrod, L.E., Allen, J.B., & Cabacungan, L.R. (2001, Sep.). Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. *Archives of Physical Medicine and Rehabilitation*. 82:1270-3. 10.1053/apmr.2001.23848
- Pisters, R., Lane, D.A, Nieuwlaat, R., de Vos, C.B., Crijns, H.F., & Lip, G.Y. (2010, Nov.). A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. *CHEST*. 138(5):1093-100. 10.1378/chest.10-0134
- Pollack, C.V., Reilly, P.A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R.A., Dubiel, R., Huisman, M.V., Hylek, E.M., Kamphuisen, P.W., Kreuzer, J., & Levy, J.H. (2015, Aug. 6). Idarucizumab for dabigatran reversal. *New England Journal of Medicine*. 373:511-520. 10.1056/NEJMoa1502000

- Seaburg, L., Hess, E.P., Coylewright, M., Ting, H.H., McLeod, C.J., & Montori, V.M. (2014, Feb. 11). Shared decision making in atrial fibrillation: Where we are and where we should be going. *Contemporary Reviews in Cardiovascular Medicine*.  
<https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.113.004498>
- Shehab, N., Lovegrove, M.C., Geller, A.I., Rose, K.O., Weidle, N.J., & Budnitz, D.S. (2016, Nov. 22). US emergency department visits for outpatient adverse drug events 2013-2014. *Journal of the American Medical Association*. 316(20):2115-2125. 10.1001/jama.2016.16201
- Spyropoulos, A. C., Giannis, D., Cohen, J., John, S., Myrka, A., Inlall, D., ... Wang, J. J. (2020). Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study. *Clinical and Applied Thrombosis/Hemostasis*. <https://doi.org/10.1177/1076029620925910>
- Stacey, D., Legare, F., Col, N.F., Bennett, C.L., Barry, M.J., Eden, K.B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., & Wu, J.H. (2014, Jan. 28). Decision aids for people facing health treatment or screening decisions. *The Cochrane Database of Systematic Reviews*. 1:CD001431. 10.1002/14651858.CD001431.pub4
- Steinberg, B.A., Shrader, P., Thomas, L., Ansell, J., Fonarow, G.C., Gersh, B.J., Kowey, P.R., Mahaffey, K.W., Naccarelli, G., Reiffel, J., Singer, D.E., Peterson, E.D., Piccini, J.P., & ORBIT-AF Investigators and Patients. (2016, Dec. 20). Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. *Journal of the American College of Cardiology*. 68(24):2597-2604. 10.1016/j.jacc.2016.09.966
- Stevens, S.M., Woller, S.C., Bauer, K.A., Kasthri, R., Cushman, M., Strieff, M., Lim, K., & Douketis, J.D. (2016, Jan.16). Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. *Journal of Thrombosis and Thrombolysis*. 41: 154.  
<https://doi.org/10.1007/s11239-015-1316-1>
- U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. (n.d.). *Adverse Drug Events*. <https://health.gov/our-work/health-care-quality/adverse-drug-events>
- U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. (2014). *National action plan for adverse drug event prevention*.  
<https://health.gov/hcq/pdfs/ade-action-plan-508c.pdf>
- U.S. Food and Drug Administration. (2019, May 3). *Warfarin INR Test Meters*.  
<https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/WarfarinINRTestMeters/default.htm>.
- Western Australia Anticoagulation Steering Group. (n.d.). *Safe management of anticoagulants in WA hospitals*. [PowerPoint]. <https://docplayer.net/15751184-Safe-management-of-anticoagulants-in-wa-hospitals.html>
- Wilke, T., Groth, A., Mueller, S., Pfannkuche, M., Verheyen, F., Linder, R., Maywald, U., Kohlmann, T., Feng, Y.S., Breithardt, G., & Bauersachs, R. (2012, Jun.). Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and

its clinical outcomes, based on claims-data of 183,448 patients. *Thrombosis and Haemostasis*. 107(6):1053-1065. 10.1160/TH11-11-0768

Yao, X., Shah, N.D., Sangaralingham, L.R., Gersh, B.J., & Noseworthy, P.A. (2017, Jun. 13). Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. *Journal of the American College of Cardiology*. 69(23):2779-2790. 10.1016/j.jacc.2017.03.600